Literature DB >> 27389037

Investigation of the cytotoxic implications of metal chelators against melanoma and approaches to improve the cytotoxicity profiles of metal coordinating agents.

Fady N Akladios1, Scott D Andrew1, Christopher J Parkinson2.   

Abstract

The cytotoxic activity of thiosemicarbazones (TSC) and thiocarbohydrazones was investigated against the MelRm melanoma cell line. In general, the melanoma line was susceptible to metal coordinating agents, the most useful of which incorporated the dipyridyl ketone hydrazone sub-structure. The impact of copper supplementation on the cytotoxic activity towards the melanoma line (MelRm) of metal coordinating agents when acting as ionophores is less predictable than the general improvement that has been seen in other cancer cells such as breast adenocarcinoma (MCF-7). The bimetallic nature of thiocarbohydrazone complexes with resultant loss of lipophilicity is a limiting factor in usage against MelRm. The cytotoxic activity of TSC against MelRm when used as copper ionophores could be markedly improved through combination with a partner drug capable of disrupting cellular defences to oxidative stress. In the absence of copper supplementation, both TSC and thiocarbohydrazones could be used to initiate cell cycle arrest and this could be employed to improve cytotoxicity profiles of other metallodrugs such as cisplatin.

Entities:  

Keywords:  Cisplatin; Copper Thiosemicarbazone; Melanoma; Metal chelation; Metal transport; Reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2016        PMID: 27389037     DOI: 10.1007/s10534-016-9945-1

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  2 in total

1.  The role of oxidative stress in activity of anticancer thiosemicarbazones.

Authors:  Katarzyna Malarz; Anna Mrozek-Wilczkiewicz; Maciej Serda; Marta Rejmund; Jaroslaw Polanski; Robert Musiol
Journal:  Oncotarget       Date:  2018-04-03

2.  Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma.

Authors:  Sotiris Kyriakou; Melina Mitsiogianni; Theodora Mantso; William Cheung; Stephen Todryk; Stephany Veuger; Aglaia Pappa; David Tetard; Mihalis I Panayiotidis
Journal:  Invest New Drugs       Date:  2019-06-26       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.